Be at Med-e-Tel 2009 to Meet a Highly Qualified eHealth Audience

1-3 April, 2009, Luxembourg
An extensive international program with participants from 50 countries in Europe and around the world will put your company and solutions in front of an audience that is looking to see and hear the latest developments in telemedicine and eHealth. Supported by the International Society for Telemedicine & eHealth, European Commission, World Health Organization, International Telecommunication Union, European Association of CyberTherapy & Rehabilitation, and a range of other associations, the Med-e-Tel event gathers European and global healthcare leaders and providers.

A regional seminar, specifically targeted at healthcare administrators and professionals, is the ideal opportunity to profile your company and services among local stakeholders and to develop your business in the Luxembourg and Belgian marketplace. The seminar is an integral part of the Med-e-Tel conference program and is endorsed by the Luxembourg Ministry of Health and the CRP-Santé (Public Institute for Research in Healthcare, Public Health and Biotechnology).

Products and services on display, include:

  • computer hard/software and peripherals
  • consulting services
  • diagnostic/monitoring systems and devices
  • electronic health cards
  • electronic medical records and personal health records
  • hospital information systems
  • imaging devices
  • internet/intranet services
  • mobile/wireless devices
  • satellite communication
  • secure data transmission
  • surgical systems
  • systems integration
  • telecommunication services and devices
  • telecare/telehealth/telemedicine equipment and assistive technologies
  • videoconferencing
  • vital signs monitoring

Benefits and marketing opportunities for sponsors and exhibitors include:

  • stand space on the Med-e-Tel expo and catering area
  • extensive coverage in the Med-e-Tel newsletters
  • acknowledgement on the Med-e-Tel website
  • opportunity to make presentations or hold a workshop in the Med-e-Tel conference program
  • access to business lounge to organize client or sales meetings and presentations during the event
  • access to all conference sessions (an incredible educational, learning and networking experience!) for your personnel and invitees
  • advertising in the Conference and Exhibition Guide
  • signage at the event and in the conference rooms
  • coverage in international trade press
  • conference bag inserts
  • coffee break, lunch or reception sponsorships
  • access to delegate list
  • unlimited networking opportunities during the entire three days of the event, including two special networking receptions

Profile your company or organization as a major player in ehealth and telemedicine and gain valuable access to health, industry and government decision makers. To discuss sponsorship, exhibiting and presentation opportunities, send an e-mail at This email address is being protected from spambots. You need JavaScript enabled to view it.

For further information, please visit:
http://www.medetel.eu

About Med-e-Tel
Med-e-Tel focuses on ehealth and telemedicine applications and a wide range of other medical ICT applications and on the convergence of information and communication technology with medical applications, which lead to higher quality of care, cost reductions, workflow efficiency, and widespread availability of healthcare services.

The "Med" in Med-e-Tel stands for healthcare services (institutional and home based care, prevention and education) and for medical products and equipment (medical imaging equipment, monitoring devices, electronic health records, etc.).
The "e" stands for the electronic and IT industry and services (hard- & software, internet, e-mail, etc.).
The "Tel" stands for telecommunications (whether it is POTS, ISDN, wireless, satellite, videoconferencing, VoIP, or other).

For further information, please visit www.medetel.lu.

Most Popular Now

NextPoint Therapeutics announces $80 million Serie…

NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced today that it raised $80 million in Series B financing co-l...

AstraZeneca to acquire CinCor Pharma to strengthen…

AstraZeneca has entered into a definitive agreement to acquire CinCor Pharma, Inc. (CinCor), a US-based clinical-stage biopharmaceutical company, focused on developing no...

Bayer to accelerate drug discovery with Google Clo…

Bayer AG and Google Cloud announced a collaboration to drive early drug discovery that will apply Google Cloud's Tensor Processing Units (TPUs), which are custom-develope...

Incurable liver disease may prove curable

Research led by Associate Professor Duc Dong, Ph.D., has shown for the first time that the effects of Alagille syndrome, an incurable genetic disorder that affects the li...

Scientists develop a cancer vaccine to simultaneou…

Scientists are harnessing a new way to turn cancer cells into potent, anti-cancer agents. In the latest work from the lab of Khalid Shah, MS, PhD, at Brigham and Women’s ...

Acquisition of Neogene Therapeutics completed

AstraZeneca has completed the acquisition of Neogene Therapeutics Inc. (Neogene), a global clinical-stage biotechnology company pioneering the discovery, development and ...

Study identifies potential new approach for treati…

Targeting iron metabolism in immune system cells may offer a new approach for treating systemic lupus erythematosus (SLE) - the most common form of the chronic autoimmune...

Nanotechnology may improve gene therapy for blindn…

Using nanotechnology that enabled mRNA-based COVID-19 vaccines, a new approach to gene therapy may improve how physicians treat inherited forms of blindness. A collabo...

Modified CRISPR-based enzymes improve the prospect…

Many genetic diseases are caused by diverse mutations spread across an entire gene, and designing genome editing approaches for each patient’s mutation would be impractic...

Pfizer expands 'An Accord for a Healthier World' p…

Pfizer Inc. (NYSE: PFE) announced that it has significantly expanded its commitment to An Accord for a Healthier World to offer the full portfolio of medicines and vaccin...

500,000 missed out on blood pressure lowering drug…

Nearly half a million people missed out on starting medication to lower their blood pressure during the COVID-19 pandemic, according to research supported by the British ...

Roche announces the European Commission approval o…

Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that the European Commission (EC) has approved Xofluza® (baloxavir marboxil) in children aged one year and above for the trea...